Fjar.ang.s, Sweden

Nils O Nilsson

This inventor holds 1 USPTO granted patent. Top assignee: Aktiebolaget Astra. Active years: 1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nils O Nilsson. Retrieved from https://idiyas.com/inventor/nils-o-nilsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nils O Nilsson: Innovator in Peptide Derivatives

Introduction

Nils O Nilsson is a notable inventor based in Fjärås, Sweden. He has made significant contributions to the field of biochemistry, particularly in the development of peptide derivatives. His work focuses on creating compounds that serve as essential starting materials for synthesizing serine protease inhibitors.

Latest Patents

Nils O Nilsson holds 1 patent for his invention related to peptide derivatives. The patent concerns a compound of a specific formula and its protected forms and salts. This invention plays a crucial role in an improved method of synthesizing serine protease inhibitors, which are vital in various therapeutic applications.

Career Highlights

Nils is associated with Aktiebolaget Astra, a prominent company in the pharmaceutical industry. His work at the company has allowed him to contribute to innovative solutions in drug development and biochemistry.

Collaborations

Throughout his career, Nils has collaborated with esteemed colleagues, including Karl Thomas Antonsson and Ruth Elvy Bylund. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Nils O Nilsson's contributions to the field of peptide derivatives and serine protease inhibitors highlight his innovative spirit and dedication to advancing biochemistry. His work continues to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…